TITLE

Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

AUTHOR(S)
Shankaran, Veena; Mummy, David; Koepl, Lisel; Blough, David; Yeun Mi Yim; Yu, Elaine; Ramsey, Scott
PUB. DATE
September 2013
SOURCE
Clinical Colorectal Cancer;Sep2013, Vol. 12 Issue 3, p204
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
90488659

 

Related Articles

  • Nursing Considerations of Bevacizumab Use in Multiple Tumor Types. Gobel, Barbara Holmes // Oncology Nursing Forum;May2007, Vol. 34 Issue 3, p693 

    Purpose/Objectives: To update information concerning the antiangiogenic agent bevacizumab, discuss side effects, and provide information on nursing management of the side effects. Data Sources: Published articles, abstracts, and research data. Data Synthesis: In clinical trials, the addition of...

  • Managing patients with metastatic colorectal cancer on bevacizumab. Lemmens, Liesbeth; Claes, Viviane; Uzzell, Maggie // British Journal of Nursing;8/14/2008, Vol. 17 Issue 15, p944 

    Bevacizumab (Avastin®) is a humanized monoclonal antibody that inhibits the activity of vascular endothelial growth factor (VEGF), a key molecule controlling tumour blood vessel formation (angiogenesis). By inhibiting VEGF and thus tumour angiogenesis, bevacizumab inhibits tumour growth and...

  • Bevacizumab and arterial thromboembolic events.  // WHO Drug Information;2005, Vol. 19 Issue 1, p25 

    The article informs that the manufacturer of bevacizumab has drawn attention to an increased risk of arterial thromboembolic events associated with the use of bevacizumab in combination with chemotherapy. These events included cerebral infarction, transient ischemic attacks, myocardial...

  • Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer. STRICKLER, JOHN H.; HURWITZ, HERBERT I. // Oncologist;Apr2012, Vol. 17 Issue 4, p513 

    Since its approval for the first-line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become a standard treatment option in combination with chemotherapy for patients with mCRC. Bevacizumab has demonstrated efficacy in combination with a number of different backbone...

  • Bevacizumab + FOLFIRI cost effective in Korea?  // PharmacoEconomics & Outcomes News;7/9/2011, Issue 632, p7 

    This article reports on a study on the cost effectiveness of bevacizumab in combination with a FOLFIRI chemotherapy regimen for the treatment of patients with metastatic colorectal cancer (mCRC).

  • Adverse Reaction Research.  // Reactions Weekly;11/15/2008, Issue 1228, p3 

    The article discusses research being done on preoperative bevacizumab. It references a study by S. B. Kesmodel et al published in the November 10, 2008 issue of the "Journal of Clinical Oncology." The study concluded that the addition of bevacizumab to preoperative chemotherapy is not associated...

  • Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Cassidy, James; Saltz, Leonard B.; Giantonio, Bruce J.; Kabbinavar, Fairooz F.; Hurwitz, Herbert I.; Rohr, Ulrich-Peter // Journal of Cancer Research & Clinical Oncology;May2010, Vol. 136 Issue 5, p737 

    Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy for patients with metastatic colorectal cancer (mCRC). The relative benefit of bevacizumab in older patients has not been widely studied and is of interest. This retrospective analysis used data from three first-line...

  • Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Cortes, J.; Calvo, V.; Ramírez-Merino, N.; O'Shaughnessy, J.; Brufsky, A.; Robert, N.; Vidal, M.; Muñoz, E.; Perez, J.; Dawood, S.; Saura, C.; Di Cosimo, S.; González-Martín, A.; Bellet, M.; Silva, O. E.; Miles, D.; Llombart, A.; Baselga, J. // Annals of Oncology;May2012, Vol. 23 Issue 5, p1130 

    Background: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse...

  • Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients. Saito, Seiya; Hayashi, Naoko; Sato, Nobutaka; Iwatsuki, Masaaki; Baba, Yoshifumi; Sakamoto, Yasuo; Miyamoto, Yuji; Watanabe, Masayuki; Yoshida, Minoru; Sakai, Kenji; Katsumori, Takashi; Katahuchi, Shigeru; Shigaki, Nobuyuki; Yamada, Kazutaka; Kimura, Masami; Tanigawa, Tomio; Takano, Sadamu; Kuramoto, Masafumi; Baba, Hideo // International Journal of Clinical Oncology;Aug2013, Vol. 18 Issue 4, p689 

    Background: There has so far been little information on the clinical effect of bevacizumab against colorectal cancer in Japan. Hence, this study was conducted to retrospectively evaluate the safety and efficacy of bevacizumab in clinical practice. Methods: A total of 181 patients with metastatic...

  • Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer. De Gramont, Aimery; Van Cutsem, Eric // Oncology;2005 Supplement 3, Vol. 69, p46 

    Bevacizumab (Avastin®) has unprecedented survival benefit in patients with metastatic colorectal cancer. Trials are already in progress to investigate the potential of bevacizumab in indications including metastatic renal cell cancer (RCC), non-small cell lung cancer (NSCLC), pancreatic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics